If a Stock Market Crash Is Coming, History Says Buying and Holding These Stocks Is a Smart Move

The article recommends a buy-and-hold strategy for weathering inevitable bear markets, highlighting that the S&P 500 has historically recovered from all downturns. It suggests focusing on dividend-paying stocks in defensive sectors like healthcare and consumer staples, particularly Dividend Kings that have increased dividends for 50+ years, as these provide stability and income during market volatility.

08/22/2026, 8:15 AM • The Motley Fool

Warren Buffett Thinks Investors Are "Gambling" and "Playing With Fire" Right Now. But Here Are 3 Safe Stocks Even the Oracle of Omaha Would Like.

Warren Buffett warns that investors are gambling in the current market environment with excessive speculation. The article recommends three defensive stocks that could perform well during a market correction: Johnson & Johnson, PepsiCo, and Waste Management. These companies offer stability through strong dividend growth histories, quality business models, and resilience during economic downturns.

08/19/2026, 10:30 AM • The Motley Fool

Fidelity Healthcare ETF vs. iShares Pharma Fund: Which Wins?

Fidelity MSCI Health Care Index ETF (FHLC) and iShares U.S. Pharmaceuticals ETF (IHE) offer different approaches to healthcare investing. FHLC provides broad diversification across 338 healthcare holdings with a lower 0.08% expense ratio, while IHE focuses on 56 pharmaceutical stocks with higher concentration risk but delivered 60% one-year returns. The analysis recommends FHLC for its superior diversification and lower costs, despite IHE's recent outperformance.

08/14/2026, 7:15 AM • The Motley Fool

Simplify's PINK or iShares' IYH: Which Healthcare ETF Should Long-Term Investors Choose Right Now?

Simplify Health Care ETF (PINK) has delivered superior 1-year returns of 42% versus iShares U.S. Healthcare ETF's (IYH) 31.4%, driven by active management focused on healthcare innovation and a charitable mission donating profits to cancer research. However, IYH offers lower costs (0.38% vs 0.51% expense ratio), higher dividend yield (1.1% vs 0.6%), and a proven 25+ year track record, making it the more suitable choice for most long-term conservative investors despite PINK's recent outperformance.

08/13/2026, 3:34 PM • The Motley Fool

The U.S. Labor Market Is Weakening. These 2 Dividend Stocks Look Built to Weather a Recession

With the July 2026 Jobs Report showing weaker-than-expected hiring and recession concerns rising, the article recommends two dividend stocks as recession-resistant investments: Johnson & Johnson and Abbott Laboratories. Both are Dividend Kings with strong core businesses in healthcare that should remain resilient during economic downturns.

08/11/2026, 5:30 PM • The Motley Fool

Johnson & Johnson Has Increased Its Dividend for 64 Consecutive Years. Here's How Much $10,000 Invested in the Dividend King Pays Annually.

Johnson & Johnson maintains its status as a Dividend King with 64 consecutive years of dividend increases. A $10,000 investment would generate approximately $210 annually at the current 2.1% dividend yield. While dividend growth has been modest at 5.3% annually over the past decade, J&J is increasingly positioned as a growth stock following strategic acquisitions in oncology, with the stock gaining nearly 80% since end of 2024.

08/09/2026, 9:15 AM • The Motley Fool

Competition Is Heating Up, but Here's Why Intuitive Surgical Might Still Be the Smartest Bet in MedTech

Intuitive Surgical faces new competition from Medtronic and Johnson & Johnson in the surgical robotics space, but maintains a strong market position with 11,710 da Vinci systems in use globally. The company's real strength lies in its recurring revenue from instruments, accessories, and services (75% of revenue), rather than system sales alone. Despite a 40% stock decline and a 42x P/E ratio, the company's large installed base and annuity-like income streams provide a competitive moat that positions it favorably for growth-oriented investors.

08/08/2026, 12:15 PM • The Motley Fool

iShares Global Healthcare ETF vs State Street SPDR Biotech ETF. Which Healthcare-Focused Fund Will Bring You Profits in 2026 and Beyond?

The article compares two healthcare-focused ETFs: iShares Global Healthcare ETF (IXJ) and State Street SPDR S&P Biotech ETF (XBI). XBI delivered superior 1-year returns of 80.2% with small-cap biotech focus but carries higher volatility (54% max drawdown). IXJ offers more stability with lower volatility, higher dividend yield (1.4%), and international diversification across large-cap pharmaceutical and healthcare companies. The analysis recommends XBI for long-term investors prioritizing performance despite greater risk.

08/08/2026, 12:02 PM • The Motley Fool

Vanguard Health Care ETF vs State Street XLV: Which ETF Is the Better Buy for Investors in 2026?

The article compares two healthcare sector ETFs: Vanguard Health Care ETF (VHT) with 423 holdings and State Street Health Care Select Sector SPDR ETF (XLV) with 60 holdings. While XLV has slightly lower expenses (0.08% vs 0.09%) and better 5-year returns, VHT outperforms on 1-year returns and offers broader diversification. The analysis recommends VHT for long-term investors due to superior recent performance and lower concentration risk.

08/08/2026, 11:33 AM • The Motley Fool

Worried About the Market? These Stocks Have a Track Record of Helping Investors Sleep at Night.

The article recommends three healthcare dividend growth stocks for investors seeking portfolio stability during market volatility: Johnson & Johnson (a Dividend King with 64 consecutive years of dividend increases), UnitedHealth Group (rebounding after recent challenges with a 2.26% yield), and McKesson (the largest U.S. pharmaceutical distributor with steady dividend growth). Healthcare is highlighted as a defensive sector due to non-discretionary spending patterns.

08/06/2026, 10:15 AM • The Motley Fool

State Street XLV vs VanEck BBH: Which Healthcare ETF Is the Better Buy in 2026?

State Street's XLV healthcare ETF offers broader exposure with lower costs (0.08% expense ratio) and higher dividend yield (1.6%), delivering 30% more growth over five years with lower volatility. VanEck's BBH biotech ETF provides concentrated exposure to 25 biotech stocks with higher recent returns but greater risk, making XLV the better choice for long-term investors seeking defensive characteristics.

08/05/2026, 3:02 PM • The Motley Fool

Helus Pharma Appoints Michael Halstead as Chief Executive Officer

Helus Pharma announced the appointment of Michael Halstead as Chief Executive Officer, effective immediately. Halstead brings 25 years of pharmaceutical industry experience, including his recent role as President of Intra-Cellular Therapies during its $14.6 billion acquisition by Johnson & Johnson. The appointment comes as Helus Pharma completes enrollment in the APPROACH Phase 3 study of HLP003 for adjunctive treatment of Major Depressive Disorder, with topline data expected in Q4 2026.

08/03/2026, 7:40 AM • GlobeNewswire

XLV vs. IBBQ: Is Broad Healthcare Exposure or Biotech Growth the Better ETF Buy?

XLV, a broad healthcare ETF, offers lower costs (0.08% expense ratio) and higher dividend yield (1.60%) with more stability, while IBBQ, a concentrated biotech ETF, delivered stronger one-year returns (45.52% vs 26.79%) but with significantly higher volatility and drawdown risk. The choice depends on investor risk tolerance and investment objectives.

08/01/2026, 5:11 PM • The Motley Fool

Prediction: Eli Lilly Will Be Worth $2 Trillion by 2031

Eli Lilly is positioned to become the first healthcare company to reach a $2 trillion market cap by 2031, requiring a 12.7% compound annual growth rate. The company's GLP-1 drug portfolio, led by tirzepatide (Mounjaro/Zepbound), is expected to drive strong revenue growth despite increasing competition. Additional growth catalysts include new product launches like Foundayo, pipeline candidates such as retatrutide, and AI-driven cost efficiencies across the organization.

08/01/2026, 4:17 PM • The Motley Fool

Healthcare Stocks Are Having a Good Year. Should You Buy a Fidelity or iShares ETF to Profit?

The article compares two healthcare-focused ETFs: Fidelity MSCI Health Care Index ETF (FHLC) and iShares U.S. Healthcare ETF (IYH). FHLC is recommended as the better choice due to its significantly lower expense ratio (0.08% vs 0.38%), broader diversification with 334 holdings versus 100, and consistent outperformance across multiple time periods. Over 10 years, a $10,000 investment in FHLC would have yielded approximately $1,900 more than IYH.

08/01/2026, 1:28 PM • The Motley Fool